FUJIFILM Archives | Page 2 of 4

FUJIFILM CDI Partners with UC Irvine to Commercialize iPSC-derived Microglia & Media

June 6, 2018 By Cade Hildreth, Founder & President Leave a Comment

FUJIFILM Cellular Dynamics licenses University of California – Irvine’s technologies for derivation of microglia

MADISON, Wis., June 6, 2018 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, announced today that it has entered into an exclusive patent license agreement with the University of California – Irvine (UCI) through its offices at UCI Applied Innovation to license and commercialize UCI’s technologies for derivation of microglia in the commercial research field and also a non-exclusive patent license agreement to commercialize microglia media formulation. [Read more…]

Fujifilm and Takeda To Co-Develop Regenerative Therapies Using iPS Cell-Derived Cardiomyocytes

February 9, 2018 By Cade Hildreth, Founder & President Leave a Comment

FUJIFILM Corporation and Takeda Pharmaceutical have announced they will partner to develop regenerative therapies using iPS cell-derived cardiomyocytes produced by Fujfilm’s subsidiary, Cellular Dynamics International (CDI).

As stated by Aiichiro Hiruma, General Manager of Regenerative Medicine Division at FUJIFILM Corporation:

“We are delighted to initiate this partnership applying practical use of our iPSC-derived cardiac cells with Takeda, which has abundant experience in drug development and clinical trials. In addition to establishing new treatment methods for patients with heart disease, Fujifilm and Takeda will contribute to the elevation of regenerative medication business to the industrial stage by applying our engineering technologies to manufacture high-quality cells safely and efficiently.”

At its core, the partnership will align manufacturing technology possessed by Cellular Dynamics International, an affiliate company of Fujifilm, with Takeda’s iPSC expertise and research to be conducted by the Center for iPS Cell Research and Application (CiRA) at Kyoto University. Together, these synergies will support pre-clinical and clinical studies for regenerative medicines that will address unmet cardiac needs, with a focus on heart failure. [Read more…]

Cellular Dynamics International Sends iPSCs to International Space Station on NASA Resupply Mission

December 27, 2017 By Cade Hildreth, Founder & President Leave a Comment

MADISON, Wis., Dec. 27, 2017— Cellular Dynamics International (CDI), a FUJIFILM company, the leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSC-cells, announced that its iCell® Cardiomyocytes were launched into space via SpaceX’s 13th commercial resupply services mission to the International Space Station on Dec.15, 2017. The purpose of the scientific research project utilizing CDI’s iCell Cardiomyocytes in space is to validate the function of NASA’s new Bioculture System for automated cell culture on the International Space Station and to study human cardiac cell function in microgravity. [Read more…]

Cynata Therapeutics Lands Japanese Giant Fujifilm

March 28, 2017 By Cade Hildreth, Founder & President Leave a Comment

It is not every day that an Aussie minnow lands a deal with a Japanese whale. When Fujifilm took a 9% equity stake in Cynata Therapeutics Ltd (ASX: CYP), it was a major lift for the regenerative medicine company, positioning Cynata to benefit not only from Fujifilm’s resources but also more broadly from current economic strategy within Japan.

Prime Minister of Japan, Shinzō Abe, has committed to building leadership around a new generation of regenerative medicine products involving human cells and tissues and Cynata is now perfectly positioned to take advantage of this in the world’s second largest market for healthcare products. [Read more…]

Dr Paul Wotton appointed as Chairman of the Cynata Board

March 2, 2017 By Cade Hildreth, Founder & President Leave a Comment

Melbourne, Australia; 28 February 2017 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP) is pleased to announce the appointment of existing nonexecutive director Dr Paul Wotton as Chairman of the Board of Directors. With Cynata now transitioning to a clinical stage company, the Board believes that Dr Wotton has the skills, focus and proven track record to help steer the Company effectively through this next stage of growth. Past chairman Dr Stewart Washer will remain on the Board as a non-executive Director. [Read more…]